NEWS SOURCE: Epeius Biotechnologies Corporation
Precision-targeted Reximmune-C® recruits cancer patient’s inner SWAT team.
SAN MARINO, Calif., March 16 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.
The advent of pathotropic (disease-seeking) targeting technology first enabled the development of tumor-targeted Rexin-G, which seeks-out, accumulates-in, and selectively delivers a lethal designer gene to tumors that have spread throughout the body (metastatic cancer), halting the progression of disease while improving both survival and quality-of-life. Approved for all solid tumors in the Philippines, Rexin-G has received Orphan Drug and Fast Track status from the U.S. FDA, and is currently moving on to Phase III trials for first-line and second-line indications.
Once the control of tumor growth has been achieved with Rexin-G®, the need to extend the treatment intervals and/or clinical remissions led to the development of Reximmune-C, a second tumor-targeted genetic medicine which delivers a pulse of immune-stimulating cytokine directly to the sites of residual or recurrent disease, thereby recruiting the patient’s own immune system into the lesions of the residual cancer to invoke a more lasting anti-tumor immune response.
Much like a SWAT (special weapons and tactics) Team that calls an elite police force to the scene of a crime, Reximmune-C acts at the local level, recruiting the body’s own professional immune cells, antigen-presenting cells, helper cells, and killer T-cells directly to the locus of the residual cancer, where tumor debris as antigens are abundant.
This provides the patient with an opportunity to mount a beneficial immune response that would further improve clinical outcome. Unlike, previous approaches to personalized cancer vaccination, a simple intravenous infusion of tumor-targeted Reximmune-C marshals the cadre of complex immunological responses of this intrinsic SWAT Team to the place where it is needed most. By reaching beyond the boundaries of medicine to the very crux of metastatic disease, Epeius delivers another vital innovation.
About Epeius Biotechnologies:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.
To learn more about our pipeline of proprietary biotechnologies, please visit us at www.epeiusbiotech.com.
News issued by: Epeius Biotechnologies Corporation
Original Image: https://www.send2press.com/wire/images/10-0316-epeiusbiotech_72dpi.jpg
# # #
Original Story ID: (5770) :: 2010-03-0316-002
Original Keywords: Epeius Biotechnologies Corporation, tumor targeted immunotherapy, metastatic cancer treatment, bio medicine patents, pharma, California tech news, Rexin-G, Reximmune-C, genetic medicine, Orphan Drug and Fast Track status from the US FDA, vaccine technology for cancer Epeius Biotechnologies Corporation San Marino California
Alternate Headline: Epeius Bio’s Precision-targeted Reximmune-C recruits cancer patient’s inner SWAT team
NEWS ARCHIVE NOTE: this archival news content, issued by the news source via Send2Press Newswire, was originally located in the Send2Press® 2004-2015 2.0 news platform and has been permanently converted/moved (and redirected) into our 3.0 platform. Also note the story “reads” counter (bottom of page) does not include any data prior to Oct. 30, 2016. This press release was originally published/issued: Tue, 16 Mar 2010 06:58:47 +0000
NEWS SOURCE: Epeius Biotechnologies Corporation | Published: 2010-03-16 06:58:47
IMPORTANT NOTICE FOR ARCHIVAL CONTENT ABOVE: The above archival press release content was issued on behalf of the noted "news source" who provided the content (text and image[s]) and is solely responsible for its accuracy. Links may not work if very old; use such with caution. Send2Press does not represent the "news source" in any capacity. For questions about this content contact the company/person mentioned directly. To report fraud or illegal material, or DMCA complaints, please contact Send2Press via our main site (any such complaints must be made in writing, not by phone).
